Merck Frosst has announced today the approval in Canada of a first of its class in cancer treatment, (Pr)ZOLINZA(TM) (vorinostat capsules) for advanced CTCL (cutaneous T-cell lymphoma), a rare form of non-Hodgkins lymphoma which affects mainly the skin.
The details can be read here.
No comments:
Post a Comment